The FY2023 (Dec) proxy of CRISPR Therapeutics AG names 19 peer companies for pay. Among CRISPR Therapeutics AG and these peers, CEO pay was 3rd highest of 6 and total shareholder return was 5th highest of 6.
3rd highest of 6in CRISPR Therapeutics AG and its pay peers, FY2023 (Dec) by CEO pay:
$6.3M$15.8M
5th highest of 6in CRISPR Therapeutics AG and its pay peers, FY2023 (Dec) by total shareholder return:
$84$166
Pay peer group, FY2023 (Dec) proxy
| Neurocrine Biosciences | ||
| Ionis Pharmaceuticals | ||
| BridgeBio Pharma | ||
| Alnylam Pharmaceuticals | ||
| Beam Therapeutics | ||
| Allogene Therapeutics | Not disclosed | Not disclosed |
| Apellis Pharmaceuticals | Not disclosed | Not disclosed |
| Arrowhead Pharmaceuticals | Not disclosed | Not disclosed |
| Blueprint Medicines | Not disclosed | Not disclosed |
| Cerevel Therapeutics | Not disclosed | Not disclosed |
| Denali Therapeutics | Not disclosed | Not disclosed |
| Editas Medicine | Not disclosed | Not disclosed |
| Fate Therapeutics | Not disclosed | Not disclosed |
| Intellia Therapeutics | Not disclosed | Not disclosed |
| Iovance BioTherapeutics | Not disclosed | Not disclosed |
| Mirati Therapeutics | Not disclosed | Not disclosed |
| Sarepta Therapeutics | Not disclosed | Not disclosed |
| Ultragenyx Pharmaceutics | Not disclosed | Not disclosed |
| Vir Biotechnology | Not disclosed | Not disclosed |
19 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.